Gsa Capital Partners LLP Cassava Sciences Inc Transaction History

Gsa Capital Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$12.35 - $26.11 $305,699 - $646,300	24,753 New	24,753 $306,000
Q4 2023 Feb 16, 2024	BUY	$12.64 - $30.11 $301,072 - $717,190	23,819 New	23,819 $536,000
Q3 2021 Nov 12, 2021	SELL	$41.79 - $135.3 $213,296 - $690,571	-5,104 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$32.15 - $89.72 $164,093 - $457,930	5,104 New	5,104 $436,000
Q1 2021 May 10, 2021	SELL	$7.09 - $87.95 $132,200 - $1.64 Million	-18,646 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$6.79 - $12.25 $126,606 - $228,413	18,646 New	18,646 $127,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.